NM HB137

Retail pharmacies that stock controlled substances must maintain minimum buprenorphine inventory levels calculated every 30 days based on average daily dispensing, plus additional prescriptions (three extra for non-community pharmacies, one or two for community-based pharmacies), including both monoproduct and combination formulations

Wholesale drug distributors must submit monthly reports to the pharmacy board documenting instances where they denied, delayed, or limited buprenorphine orders from retail pharmacies, including reasons for each action

Department of Health must publish biannual reports analyzing buprenorphine access at retail pharmacies, with data aggregated to protect individual pharmacy identities

Penalties for non-compliant retail pharmacies escalate from notice (1st-2nd violation) to corrective plan (3rd violation) to fines up to $2,500 (4th+ violation within 36 months); wholesale distributors face fines up to $10,000 for repeat violations

Appropriates $1,500,000 from the general fund to the Health Care Authority for fiscal year 2027 to increase Medicaid reimbursement rates for buprenorphine prescriptions